THE FED IS IN “WAIT AND SEE” MODE, BUT KEEPS THE DOOR OPEN TO ADDITIONAL MEASURES

As widely expected the FOMC does not foresee any rate increase before end-2022, or using Chair Powel words: “We are not thinking about raising rates. We are not even thinking about thinking about raising rates”

Highlights:

  • The Fed expects quite a strong rebound, but the severe disruption caused by COVID will require rates to remain at near zero until 2022. The unemployment rate will remain high for long.
  • The May employment report was a pleasant surprise, but also an indication on how unpredictable is the outlook. This warrants waiting and learning from new data before adapting the stance.
  • Anyway, Chair Powel renewed the commitment to use aggressively all the existing tools; bond purchases will continue at least at the current pace. Further instruments, like yield curve control are being discussed.

Download the full publication below

THE FED IS IN “WAIT AND SEE” MODE, BUT KEEPS THE DOOR OPEN TO ADDITIONAL MEASURES

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
Q3 EARNINGS SEASON STARTS WELL. EXPECT STABILIZATION IN REVISIONS MOMENTUM BUT RECOVERY WILL CONTINUE
The Q3 reporting season has just started. For the US, expectations are for a yearly earnings growth of -21% after -31% in Q2. As for sectors, worse growth rates in the US are expected for energy, industrials and discretionary while pharma, utilities, IT and staples should rank better than the index.